WO1999011644A1 - Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp - Google Patents

Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp Download PDF

Info

Publication number
WO1999011644A1
WO1999011644A1 PCT/US1998/018188 US9818188W WO9911644A1 WO 1999011644 A1 WO1999011644 A1 WO 1999011644A1 US 9818188 W US9818188 W US 9818188W WO 9911644 A1 WO9911644 A1 WO 9911644A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cancer
group
formula
aromatic
Prior art date
Application number
PCT/US1998/018188
Other languages
English (en)
Inventor
Paul F. Jackson
Keith M. Maclin
Jie Zhang
Original Assignee
Guilford Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/145,185 external-priority patent/US6121278A/en
Application filed by Guilford Pharmaceuticals Inc. filed Critical Guilford Pharmaceuticals Inc.
Priority to AU92981/98A priority Critical patent/AU9298198A/en
Publication of WO1999011644A1 publication Critical patent/WO1999011644A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de formule I: ou un sel, un hydrate, un ester, un produit de solvatation, un promédicament, un métabolite, un stéréoisomère, ou des mélanges pharmaceutiquement acceptables de celui-ci, Y représentant les atomes nécessaires pour former un cycle hétérocyclique condensé, aromatique ou non aromatique, à 5 ou 6 éléments, ce cycle renfermant au moins un hétéroatome d'azote dans une relation 1,3 par rapport à l'atome d'azote décrit dans la formule I, Y pouvant être substitué ou non par au moins un alkyle, un alkényle, un cycloalkyle, un cycloalkényle, un aralkyle, un aryle, ou un oxygène à double liaison, ou un groupe -COOR5, ou un fragment choisi dans le groupe composé par: dans lequel R5 et R7 représentent indépendamment hydrogène ou alkyle, alkényle, cycloalkyle, cycloalkényle, aralkyle, ou aryle.
PCT/US1998/018188 1997-09-03 1998-09-02 Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp WO1999011644A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU92981/98A AU9298198A (en) 1997-09-03 1998-09-02 Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92252097A 1997-09-03 1997-09-03
US08/922,520 1997-09-03
US7951198A 1998-05-15 1998-05-15
US09/079,511 1998-05-15
US09/145,185 1998-09-01
US09/145,185 US6121278A (en) 1997-09-03 1998-09-01 Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity

Publications (1)

Publication Number Publication Date
WO1999011644A1 true WO1999011644A1 (fr) 1999-03-11

Family

ID=27373496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/018188 WO1999011644A1 (fr) 1997-09-03 1998-09-02 Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp

Country Status (2)

Country Link
AU (1) AU9298198A (fr)
WO (1) WO1999011644A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059973A1 (fr) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Composes de carboxamide, compositions et methodes d'inhibition de l'activite de type poly(adp-ribose) polymerase (parp)
WO2000025787A1 (fr) * 1998-10-30 2000-05-11 Guilford Pharmaceuticals Inc. Compositions pharmaceutiques contenant des inhibiteurs de poly(adp-ribose) glycohydrolase et utilisations de ces compositions
WO2001023390A2 (fr) * 1999-09-28 2001-04-05 Basf Aktiengesellschaft Derives d'azepinoindol, preparation et utilisation desdits derives
US6235748B1 (en) 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
EP1172360A1 (fr) * 1999-04-19 2002-01-16 Sankyo Company, Limited Potentialisateurs de la neurotrophine
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
WO2003020700A2 (fr) 2001-08-31 2003-03-13 Inotek Pharmaceuticals Corporation Derives d'indeno[1,2-c]isoquinoleine substitutee et procedes d'utilisation de ces composes
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6548494B1 (en) 1999-08-31 2003-04-15 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
WO2006078711A2 (fr) 2005-01-19 2006-07-27 Mgi Gp, Inc. Composes de diazabenzo[de]anthracene-3-one et utilisation dans l'inhibition de parp
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US7217709B2 (en) 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
US7381722B2 (en) 2005-02-25 2008-06-03 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
EP2033645A1 (fr) 2004-02-26 2009-03-11 Inotek Pharmaceuticals Corporation Dérivés d'isoquinoléine et leurs procédés d'utilisation
US7652028B2 (en) 2005-08-24 2010-01-26 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US8119654B2 (en) 2007-02-28 2012-02-21 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
WO2012071684A1 (fr) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Dérivés hétérocycliques, leurs procédés de préparation et leurs utilisations médicales
EP2842956A1 (fr) 2007-10-03 2015-03-04 Eisai Inc. Composés inhibiteurs de la PARP, compositions et procédés d'utilisation
US9150628B2 (en) 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
WO2016094897A1 (fr) 2014-12-12 2016-06-16 The Jackson Laboratory Compositions et méthodes se rapportant au traitement de cancers, de maladies autoimmunes et de maladies neurodégénératives
WO2016138574A1 (fr) 2015-03-02 2016-09-09 Sinai Health System Facteurs de recombinaison homologue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024379A1 (fr) * 1994-03-09 1995-09-14 Newcastle University Ventures Limited Analogues de benzamides utiles en tant qu'inhibiteurs de l'enzyme parp (adp-ribosyltransferase, adprt) de reparation de l'adn
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024379A1 (fr) * 1994-03-09 1995-09-14 Newcastle University Ventures Limited Analogues de benzamides utiles en tant qu'inhibiteurs de l'enzyme parp (adp-ribosyltransferase, adprt) de reparation de l'adn
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANASIK M ET AL: "SPECIFIC INHIBITORS OF POLY(ADP-RIBOSE) SYNTHETASE AND MONO(ADP-RIBOSYL)TRANSFERASE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 3, 25 January 1992 (1992-01-25), pages 1569 - 1575, XP000574735 *
GRIFFIN R J ET AL: "NOVEL POTENT INHIBITORS OF THE DNA REPAIR ENZYME POLY(ADP-RIBOSE)POLYMERASE (PARP)", ANTI-CANCER DRUG DESIGN, vol. 10, no. 6, September 1995 (1995-09-01), pages 507 - 514, XP002065156 *
M.J.SUTO ET AL: "DIHYDROISOQUINOLINONES:THE DESIGN AND SYNTHESIS OF A NEW SERIES OF POTENT INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE", ANTI-CANCER DRUG DESIGN, vol. 6, no. 2, May 1991 (1991-05-01), pages 107 - 117, XP002086825 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235748B1 (en) 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO1999059973A1 (fr) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Composes de carboxamide, compositions et methodes d'inhibition de l'activite de type poly(adp-ribose) polymerase (parp)
WO2000025787A1 (fr) * 1998-10-30 2000-05-11 Guilford Pharmaceuticals Inc. Compositions pharmaceutiques contenant des inhibiteurs de poly(adp-ribose) glycohydrolase et utilisations de ces compositions
US6977298B2 (en) 1999-01-11 2005-12-20 Agouron Pharmacetucals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US7429578B2 (en) 1999-01-11 2008-09-30 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
EP1172360A1 (fr) * 1999-04-19 2002-01-16 Sankyo Company, Limited Potentialisateurs de la neurotrophine
EP1172360A4 (fr) * 1999-04-19 2004-02-04 Sankyo Co Potentialisateurs de la neurotrophine
US6548494B1 (en) 1999-08-31 2003-04-15 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
WO2001023390A3 (fr) * 1999-09-28 2001-12-27 Basf Ag Derives d'azepinoindol, preparation et utilisation desdits derives
WO2001023390A2 (fr) * 1999-09-28 2001-04-05 Basf Aktiengesellschaft Derives d'azepinoindol, preparation et utilisation desdits derives
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6903079B2 (en) 2000-04-06 2005-06-07 Inotek Pharmaceuticals Corporation Nucleoside compounds and compositions thereof
EP2050750A2 (fr) 2000-05-09 2009-04-22 Cephalon, Inc. Composés multi-cycliques et leur utilisation comme inhibiteurs des enzymes PARP, VEGFR2 et MLK3
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
EP1754707A2 (fr) 2000-05-09 2007-02-21 Cephalon, Inc. Composés multicycliques et leur utilisation comme inhibiteurs des enzymes PARP, VEGFR2 et MLK3
WO2003020700A2 (fr) 2001-08-31 2003-03-13 Inotek Pharmaceuticals Corporation Derives d'indeno[1,2-c]isoquinoleine substitutee et procedes d'utilisation de ces composes
US7268143B2 (en) 2001-08-31 2007-09-11 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US7393955B2 (en) 2001-08-31 2008-07-01 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US6828319B2 (en) 2001-08-31 2004-12-07 Inotek Pharmaceuticals Corporation Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
EP2174659A1 (fr) 2001-08-31 2010-04-14 Inotek Pharmaceuticals Corporation Dérivé d'indeno[1,2-c]-isoquinoléine substitutués et utilisation de ces composés
US7217709B2 (en) 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
EP2033645A1 (fr) 2004-02-26 2009-03-11 Inotek Pharmaceuticals Corporation Dérivés d'isoquinoléine et leurs procédés d'utilisation
EP2319847A2 (fr) 2005-01-19 2011-05-11 Eisai Inc. Composés de diazabenzo[de]anthracene-3-one et méthodes pour l'inhibition de PARP
WO2006078711A2 (fr) 2005-01-19 2006-07-27 Mgi Gp, Inc. Composes de diazabenzo[de]anthracene-3-one et utilisation dans l'inhibition de parp
US7381722B2 (en) 2005-02-25 2008-06-03 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
US7652028B2 (en) 2005-08-24 2010-01-26 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US9150628B2 (en) 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
US8119654B2 (en) 2007-02-28 2012-02-21 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EP2842956A1 (fr) 2007-10-03 2015-03-04 Eisai Inc. Composés inhibiteurs de la PARP, compositions et procédés d'utilisation
WO2012071684A1 (fr) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Dérivés hétérocycliques, leurs procédés de préparation et leurs utilisations médicales
US8999985B2 (en) 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
WO2016094897A1 (fr) 2014-12-12 2016-06-16 The Jackson Laboratory Compositions et méthodes se rapportant au traitement de cancers, de maladies autoimmunes et de maladies neurodégénératives
WO2016138574A1 (fr) 2015-03-02 2016-09-09 Sinai Health System Facteurs de recombinaison homologue

Also Published As

Publication number Publication date
AU9298198A (en) 1999-03-22

Similar Documents

Publication Publication Date Title
US6121278A (en) Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6197785B1 (en) Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6635642B1 (en) PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6387902B1 (en) Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US20020160984A1 (en) Fused tricyclic compounds, methods and compositions for inhibiting parp activity
US6380193B1 (en) Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US20020028813A1 (en) Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6716828B1 (en) Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US20030105102A1 (en) Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity
US20020156050A1 (en) Carboxamine compounds, methods and compositions for inhibiting PARP activity
WO1999011622A1 (fr) Composes aminosubstitues, et procedes et compositions permettant d'inhiber l'activite de la parp
WO1999011644A1 (fr) Composes di-n-heterocycliques, et procedes et compositions permettant d'inhiber l'activite de la parp
US6395749B1 (en) Carboxamide compounds, methods, and compositions for inhibiting PARP activity
AU2005202592B2 (en) Compounds, Methods and Pharmaceutical Compositions for Treating Cellular Damage, such as Neural or Cardiovascular Tissue Damage
MXPA99011815A (es) Inhibidores de parp, composiciones farmaceuticas que los comprenden, y metodos para utilizarlos
MXPA99011814A (es) Compuestos sustituidos por alcoxilo, composiciones y metodos para inhibir la actividad de parp

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999516973

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase